Skip to main content
. 2013 Oct 30;6:1545–1552. doi: 10.2147/OTT.S32545

Figure 1.

Figure 1

Pathways and targeted therapy in BTC.

Notes: Drugs in red lettering represent agents that have been evaluated in trials that are now complete. Drugs in blue lettering represent agents that are in trials that are currently enrolling.

Abbreviations: BTC, biliary tract cancer; PDGFR, platelet-derived growth factor receptor; EGFR, epidermal growth factor receptor; HER-2, human epidermal growth factor receptor 2; VEGFR, vascular endothelial growth factor receptor; AKT, protein kinase; mTOR, mammalian target of rapamycin; MEK, mitogen-activated protein kinase.